Polymeric nanoparticle technologies for oral drug delivery.

Biologics increasingly are being used for the treatment of many diseases. These treatments typically require repeated doses administered by injection. Alternate routes of administration, particularly oral, are considered favorable because of improved convenience and compliance by patients, but physiological barriers such as extreme pH level, enzyme degradation, and poor intestinal epithelium permeability limit absorption. Encapsulating biologics in drug delivery systems such as polymeric nanoparticles prevents inactivation and degradation caused by low pH and enzymes of the gastrointestinal tract. However, transport across the intestinal epithelium remains the most critical barrier to overcome for efficient oral delivery. This review focuses on recent advances in polymeric nanoparticles being developed to overcome transport barriers and their potential for translation into clinical use.

[1]  Robert Langer,et al.  Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. , 2013, ACS nano.

[2]  R. N. Brogden,et al.  Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. , 1987, Drugs.

[3]  R. Doyle,et al.  Traveling the Vitamin B12 Pathway: Oral Delivery of Protein and Peptide Drugs , 2009 .

[4]  P. Bjorkman,et al.  The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. , 1993, Biochemistry.

[5]  M. Mullendore,et al.  In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities , 2008, Molecular Cancer Therapeutics.

[6]  K. Knopf,et al.  Estimating Patient Time Costs Associated With Colorectal Cancer Care , 2005, Medical care.

[7]  Didier Merlin,et al.  Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. , 2010, Nature materials.

[8]  N. Mantis,et al.  A Population of Langerin-Positive Dendritic Cells in Murine Peyer's Patches Involved in Sampling β-Glucan Microparticles , 2014, PloS one.

[9]  T. Yen,et al.  Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. , 2012, Molecular pharmaceutics.

[10]  B. Fleshler,et al.  Physiology of the Gastrointestinal Tract , 1969 .

[11]  E. Mathiowitz,et al.  Oral delivery of proteins by biodegradable nanoparticles. , 2013, Advanced drug delivery reviews.

[12]  D. Roopenian,et al.  Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. , 2004, Immunity.

[13]  K. Badizadegan,et al.  Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. , 1999, The Journal of clinical investigation.

[14]  J. Smart The basics and underlying mechanisms of mucoadhesion. , 2005, Advanced drug delivery reviews.

[15]  Yun-Seok Rhee,et al.  Nanomedicine in pulmonary delivery , 2009, International journal of nanomedicine.

[16]  Jinho Park,et al.  Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.

[17]  Y. Kawashima,et al.  Nanoparticles Enhance Therapeutic Efficiency by Selectively Increased Local Drug Dose in Experimental Colitis in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[18]  N. Peppas,et al.  Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  Hsing-Wen Sung,et al.  Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. , 2011, Biomaterials.

[20]  Laura M Ensign,et al.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.

[21]  G. M. Gray,et al.  Protein digestion and absorption. , 1971, Gastroenterology.

[22]  C. V. Van Itallie,et al.  Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[23]  Yves-Jacques Schneider,et al.  An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  V. Ganapathy Protein Digestion and Absorption , 2012 .

[25]  H. Fessi,et al.  Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. , 2005, Critical reviews in therapeutic drug carrier systems.

[26]  M. Postma,et al.  Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. , 2004, Clinical therapeutics.

[27]  T. Kararli Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[28]  E. Allémann,et al.  Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues , 2005, AAPS PharmSciTech.

[29]  P. Lowe,et al.  Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats , 1994, The Journal of pharmacy and pharmacology.

[30]  Zhen Gu,et al.  Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. , 2014, Chemical Society reviews.

[31]  Y. Talmon,et al.  Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption , 2013, Proceedings of the National Academy of Sciences.

[32]  Esther Jacobowitz Israel,et al.  Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells , 1997, Immunology.

[33]  P. Gorden,et al.  The use of U-500 in patients with extreme insulin resistance. , 2005, Diabetes care.

[34]  Pedro M. Valencia,et al.  Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation , 2012 .

[35]  T. Macdonald,et al.  Immunity, Inflammation, and Allergy in the Gut , 2005, Science.

[36]  E. Kaltenthaler,et al.  The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer , 2006, British Journal of Cancer.

[37]  M. Ranson,et al.  Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Yoshinori Onuki,et al.  Current challenges in non-invasive insulin delivery systems: a comparative review. , 2007, Advanced drug delivery reviews.

[39]  Saurabh Aggarwal,et al.  What's fueling the biotech engine—2011 to 2012 , 2012, Nature Biotechnology.

[40]  Yves-Jacques Schneider,et al.  Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[41]  R. James,et al.  271 Savings in staff time as a result of switching from De Gramont to oral capecitabine for patients with advance colorectal cancer , 2003 .

[42]  Hsing-Wen Sung,et al.  Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. , 2013, Advanced drug delivery reviews.

[43]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[44]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Takeuchi,et al.  A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[46]  R. Langer,et al.  Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery , 2013, Science Translational Medicine.

[47]  P Couvreur,et al.  Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. , 1997, Journal of pharmaceutical sciences.

[48]  P. Diwan,et al.  A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[49]  Hsing-Wen Sung,et al.  In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. , 2009, Biomaterials.

[50]  Thomas R. Tice,et al.  Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .

[51]  C. Sasakawa,et al.  Intestinal villous M cells: an antigen entry site in the mucosal epithelium. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[53]  Hsing-Wen Sung,et al.  A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. , 2011, Biomaterials.

[54]  C. Alexander,et al.  Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. , 2013, Small.

[55]  G. Cartenì,et al.  Cost Analysis of Capecitabine vs 5-Fluorouracil-Based Treatment for Metastatic Colorectal Cancer Patients , 2010, Journal of chemotherapy.

[56]  A. Hubbard,et al.  Transcytosis: crossing cellular barriers. , 2003, Physiological reviews.

[57]  Qiuhao Qu,et al.  Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. , 2013, Angewandte Chemie.

[58]  L. Holm,et al.  The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[59]  Robert Langer,et al.  Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. , 2007, Nanomedicine.

[60]  Sergio Grinstein,et al.  Sensors and regulators of intracellular pH , 2010, Nature Reviews Molecular Cell Biology.

[61]  Y. Schneider,et al.  Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[62]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[63]  P. Diwan,et al.  Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[64]  G. Peters,et al.  Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. , 2002, European journal of cancer.

[65]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[66]  Saurabh Aggarwal,et al.  What's fueling the biotech engine? , 2007, Nature Biotechnology.

[67]  Carino,et al.  Oral insulin delivery. , 1999, Advanced drug delivery reviews.

[68]  R. Panchagnula,et al.  Peroral route: an opportunity for protein and peptide drug delivery. , 2001, Chemical reviews.

[69]  B. Hirst,et al.  Exploiting M cells for drug and vaccine delivery. , 2001, Advanced drug delivery reviews.

[70]  David Lalezari,et al.  Gastrointestinal pH profile in subjects with irritable bowel syndrome , 2012, Annals of gastroenterology.

[71]  David J Brayden,et al.  Oral vaccination in man using antigens in particles: current status. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[72]  D. Cremaschi,et al.  Confocal analysis of fluorescent bead uptake by mouse Peyer's patch follicle‐associated M cells , 1992, Experimental physiology.

[73]  Celinda M Gourd,et al.  Oral delivery of insulin loaded poly(fumaric-co-sebacic) anhydride microspheres. , 2008, International journal of pharmaceutics.